Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA advisory panel voted 3–9 against sufficient Deramiocel efficacy evidence in DMD cardiomyopathy.
CAPRICOR THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA advisory panel voted 3–9 against sufficient Deramiocel efficacy evidence in DMD cardiomyopathy
- Non-binding recommendation creates significant approval risk for Capricor’s lead therapy
- FDA review continues despite panel vote
- BLA decision remains targeted for August 22, 2026
- DMD cardiomyopathy has no approved treatment, preserving substantial unmet-need rationale
Item EX-99.1 · Exhibit EX-99.1
- FDA advisory committee voted 3–9 against evidence supporting Deramiocel effectiveness for DMD cardiomyopathy
- Non-binding vote creates meaningful approval risk ahead of August 22, 2026 PDUFA action date
- Committee feedback was directionally supportive of Phase 3 HOPE-3 skeletal-muscle results, including PUL 2.0
- Deramiocel targets an unmet need; no approved treatment exists for DMD-related cardiac complications
- Potential Rare Pediatric Disease Priority Review Voucher remains contingent on approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CAPRICOR THERAPEUTICS, INC. 8-K filings
Get the next CAPR 8-K as it lands
Follow CAPR for push alerts, or ask the research agent what this filing means.